Display options
Share it on

J Clin Diagn Res. 2017 May;11(5):FC01-FC05. doi: 10.7860/JCDR/2017/23825.9763. Epub 2017 May 01.

A Comparative Study on Clinical and Biochemical Parameters in Amlodipine and Cilnidipine Treated Hypertensive Patients.

Journal of clinical and diagnostic research : JCDR

Kiran Shetty, Ranjan Shetty, Lakshminarayana Bairy, Pragna Rao, Amruth Kiran, Manjunath Shetty, Deepak, Vidya Nayak

Affiliations

  1. Research Scholar, Department of Cardiology, KMC, Manipal University, Manipal, Karnataka, India.
  2. Professor, Department of Cardiology, KMC, Manipal University, Manipal, Karnataka, India.
  3. Professor, Department of Pharmacology, KMC, Manipal University, Manipal, Karnataka, India.
  4. Lecturer, Department of Pharmacology, MMMC, Manipal University, Manipal, Karnataka, India.
  5. Assistant Professor, Department of Cardiovascular Technology, SOHAS, Manipal University, Manipal, Karnataka, India.

PMID: 28658794 PMCID: PMC5483696 DOI: 10.7860/JCDR/2017/23825.9763

Abstract

INTRODUCTION: Hypertension is a major health issue worldwide. Calcium Channel Blockers (CCBs) are the most commonly used antihypertensive agents. CCBs act on voltage-dependent calcium channels and they were categorized into two subclasses, Dihydropyridine (DHP) and non-Dihydropyridine (non-DHP) derivative. Amlodipine is a third generation L-type of DHP and Cilnidipine is a novel L/N-type of DHP CCB, both drugs have excellent pharmacological profiles with the unique actions.

AIM: To study the clinical and biochemical profile in Amlodipine and Cilnidipine treated mild to moderate hypertensive patients.

MATERIALS AND METHODS: The present study was a cross-sectional study. A total of 140 mild to moderate hypertensive patients (HTN classified according to Joint National Committee-8 (JNC-8) HTN guideline), 70 were in Amlodipine group (Group-A), and other 70 patients were in Cilnidipine group (Group-B). Group-A receiving Tab Amlodac 5 mg/day and Group-B receiving Tab Cilacar 10 mg/day, and both the group receiving respective medications since more than six months. Patients enrolled into the study with due consideration of eligibility criteria. Demographic, clinical and biochemical parameters were noted and compared.

RESULTS: Demographic parameters are matched, there was no significant difference seen between two study groups. Systolic and Diastolic Blood Pressure (SBP and DBP) showed a significant difference (p<0.001). There was no significant difference in pulse rate between the two groups, both QT/QTc showed statistically significant difference (p<0.001). The biochemical parameters like serum creatinine, albumin, globulin, total protein, serum Na

CONCLUSION: The Amlodipine and Cilnidipine both are equally effective antihypertensive drugs. Cilnidipine treated group showed more reduction in blood pressure than the Amlodipine treated group and there was no significant change in heart rate between the two groups. Cilnidipine group showed comparatively shortened QT/QTc interval than the Amlodipine group.

Keywords: Calcium channel blocker; Catecholamine; QT interval; Vanillyl mandelic acid

References

  1. N Am J Med Sci. 2013 Jan;5(1):47-50 - PubMed
  2. Kidney Int. 2007 Dec;72(12):1543-9 - PubMed
  3. Indian Heart J. 2013 Dec;65(6):691-5 - PubMed
  4. J Hypertens. 2014 Jun;32(6):1170-7 - PubMed
  5. Hypertens Res. 2004 Jun;27(6):379-85 - PubMed
  6. Am J Med. 2005 Dec;118 Suppl 12A:54-61 - PubMed
  7. J Clin Hypertens (Greenwich). 2013 Jul;15(7):455-7 - PubMed
  8. Ann Intern Med. 2014 Apr 1;160(7):499-503 - PubMed
  9. Hypertens Res. 2005 Dec;28(12):1003-8 - PubMed
  10. J Adv Pharm Technol Res. 2015 Apr-Jun;6(2):81-5 - PubMed
  11. J Hum Hypertens. 1991 Apr;5(2):115-9 - PubMed
  12. J Hypertens. 2002 May;20(5):993-1000 - PubMed
  13. J Hypertens. 1998 Sep;16(9):1357-69 - PubMed

Publication Types